1. Unprecedented long‐term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo‐ and immunotherapeutic regimens
   Luigi Cerbone et al, 2023, Thoracic Cancer CrossRef
2. KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
   Eugenia Lorenzini et al, 2022, NAR Cancer CrossRef
3. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics
   Esther Stern et al, 2023, Frontiers in Immunology CrossRef
4. Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma
   Shoutaro TSUJI et al, 2023, Proceedings of the Japan Academy, Series B CrossRef
5. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
   Yasuhiro Umeyama et al, 2023, Frontiers in Immunology CrossRef
6. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
   Peter T. Graham et al, 2022, Frontiers in Immunology CrossRef
7. Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies
   Tina Briolay et al, 2024, International Journal of Nanomedicine CrossRef